65 related articles for article (PubMed ID: 28424889)
1. Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer.
Korkeila EA; Salminen T; Kallio R; Mikkola M; Auvinen P; Pyrhönen S; Ristamäki R
Support Care Cancer; 2017 Sep; 25(9):2771-2777. PubMed ID: 28424889
[TBL] [Abstract][Full Text] [Related]
2. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
Bais C; Mueller B; Brady MF; Mannel RS; Burger RA; Wei W; Marien KM; Kockx MM; Husain A; Birrer MJ;
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059426
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Intensity Modulated Whole-Abdominal Radiation Therapy for High-Risk Patients With Ovarian Cancer (International Federation of Gynecology and Obstetrics Stage III): First Results of a Prospective Phase 2 Study.
Arians N; Kieser M; Benner L; Rochet N; Katayama S; Sterzing F; Herfarth K; Schubert K; Schröder L; Leitzen C; Schneeweiss A; Sohn C; Debus J; Lindel K
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):912-920. PubMed ID: 28870790
[TBL] [Abstract][Full Text] [Related]
4. Concurrent Neoadjuvant Chemotherapy and Radiation Therapy in Locally Advanced Breast Cancer.
Brackstone M; Palma D; Tuck AB; Scott L; Potvin K; Vandenberg T; Perera F; D'Souza D; Taves D; Kornecki A; Muscedere G; Chambers AF
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):769-776. PubMed ID: 28870785
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
Zhang L; Qu X; Teng Y; Shi J; Yu P; Sun T; Wang J; Zhu Z; Zhang X; Zhao M; Liu J; Jin B; Luo Y; Teng Z; Dong Y; Wen F; An Y; Yuan C; Chen T; Zhou L; Chen Y; Zhang J; Wang Z; Qu J; Jin F; Zhang J; Jin X; Xie X; Wang J; Man L; Fu L; Liu Y
J Clin Oncol; 2017 Nov; 35(31):3558-3565. PubMed ID: 28854065
[TBL] [Abstract][Full Text] [Related]
6. Codelivery of anti-cancer agents via double-walled polymeric microparticles/injectable hydrogel: A promising approach for treatment of triple negative breast cancer.
Davoodi P; Ng WC; Srinivasan MP; Wang CH
Biotechnol Bioeng; 2017 Dec; 114(12):2931-2946. PubMed ID: 28832946
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Oliver KE; Brady WE; Birrer M; Gershenson DM; Fleming G; Copeland LJ; Tewari K; Argenta PA; Mannel RS; Secord AA; Stephan JM; Mutch DG; Stehman FB; Muggia FM; Rose PG; Armstrong DK; Bookman MA; Burger RA; Farley JH
Gynecol Oncol; 2017 Nov; 147(2):243-249. PubMed ID: 28807367
[TBL] [Abstract][Full Text] [Related]
8. Taxanes in combination with platinum derivatives for the treatment of ovarian cancer during pregnancy: A literature review
.
Zheng X; Zhu Y; Zhao Y; Feng S; Zheng C
Int J Clin Pharmacol Ther; 2017 Sep; 55(9):753-760. PubMed ID: 28737125
[TBL] [Abstract][Full Text] [Related]
9. Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer.
Reeder-Hayes KE; Meyer AM; Hinton SP; Meng K; Carey LA; Dusetzina SB
J Clin Oncol; 2017 Oct; 35(29):3298-3305. PubMed ID: 28727517
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate.
Kessler ER; Gao D; Flaig TW; Breaker K; Wold M; Wacker M; Lam ET
Ann Oncol; 2017 Mar; 28(3):668. PubMed ID: 28426121
[No Abstract] [Full Text] [Related]
11. Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy.
Urruticoechea A; Rizwanullah M; Im SA; Ruiz ACS; Láng I; Tomasello G; Douthwaite H; Badovinac Crnjevic T; Heeson S; Eng-Wong J; Muñoz M
J Clin Oncol; 2017 Sep; 35(26):3030-3038. PubMed ID: 28437161
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
13. DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer.
Di Noia V; Basso M; Marsico V; Cerchiaro E; Rossi S; D'Argento E; Strippoli A; Schinzari G; Iezzi R; Cassano A; Barone C
Future Oncol; 2019 Jul; 15(20):2349-2360. PubMed ID: 28440086
[No Abstract] [Full Text] [Related]
14. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
Anderegg MCJ; van der Sluis PC; Ruurda JP; Gisbertz SS; Hulshof MCCM; van Vulpen M; Mohammed NH; van Laarhoven HWM; Wiezer MJ; Los M; van Berge Henegouwen MI; van Hillegersberg R
Ann Surg Oncol; 2017 Aug; 24(8):2282-2290. PubMed ID: 28424936
[TBL] [Abstract][Full Text] [Related]
15. A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
Infante JR; Cohen RB; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; LoRusso PM
Invest New Drugs; 2017 Oct; 35(5):576-588. PubMed ID: 28424891
[TBL] [Abstract][Full Text] [Related]
16. North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.
McWilliams RR; Foster NR; Mahoney MR; Smyrk TC; Murray JA; Ames MM; Horvath LE; Schneider DJ; Hobday TJ; Jatoi A; Meyers JP; Goetz MP
Cancer; 2017 Sep; 123(18):3494-3501. PubMed ID: 28493308
[TBL] [Abstract][Full Text] [Related]
17. Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer.
Aoyama T; Nishikawa K; Fujitani K; Tanabe K; Ito S; Matsui T; Miki A; Nemoto H; Sakamaki K; Fukunaga T; Kimura Y; Hirabayashi N; Yoshikawa T
Ann Oncol; 2017 Aug; 28(8):1876-1881. PubMed ID: 28486692
[TBL] [Abstract][Full Text] [Related]
18. Nedaplatin and irinotecan with concurrent thoracic radiotherapy followed by docetaxel consolidation in patients with locally advanced non-small cell lung cancer.
Oshita F; Murakami S; Kondo T; Saito H; Yamada K; Nakayama Y
J Exp Ther Oncol; 2017 May; 12(1):17-23. PubMed ID: 28472560
[TBL] [Abstract][Full Text] [Related]
19. Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer.
Rubovszky G; Budai B; Ganofszky E; Horváth Z; Juhos É; Madaras B; Nagy T; Szabó E; Pintér T; Tóth E; Nagy P; Láng I; Hitre E
Pathol Oncol Res; 2018 Apr; 24(2):237-244. PubMed ID: 28456898
[TBL] [Abstract][Full Text] [Related]
20. Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
Xi M; Zhang P; Zhang L; Yang YD; Liu SL; Li Y; Fu JH; Liu MZ
Jpn J Clin Oncol; 2017 Aug; 47(8):683-689. PubMed ID: 28453815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]